Oric Pharmaceuticals
ORIC
92 hedge funds and large institutions have $466M invested in Oric Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 17 closing their positions.
117% more call options, than puts
Call options by funds: $4M | Put options by funds: $1.84M
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
60% more capital invested
Capital invested by funds: $291M → $466M (+$175M)
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.71% more ownership
Funds ownership: 88.12% → 92.83% (+4.7%)
2% more funds holding
Funds holding: 90 → 92 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28M |
| 2 |
Janus Henderson Group
London,
|
+$4.77M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.39M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.77M |
| 5 |
Morgan Stanley
New York
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$7.24M |
| 2 |
Millennium Management
New York
|
-$7.04M |
| 3 |
BlackRock
New York
|
-$4.61M |
| 4 |
O
OrbiMed
New York
|
-$2.68M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.43M |
ORIC Hedge Fund Activity: Q4 2023 in Review
92 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2023, worth a combined $466M — up 60% from $291M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ORIC positions and 17 closed out — a net gain of 3 holders — while 36 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28M. The largest seller was Prosight Management, cutting an estimated $7.24M.
- 92 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2023, up from 90 in Q3 2023.
- Funds reported $466M of Oric Pharmaceuticals stock for Q4 2023, up 60% quarter-over-quarter.
- 20 funds opened new Oric Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +3 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2023 was Fidelity Investments, an estimated $28M added.
- The largest Oric Pharmaceuticals seller in Q4 2023 was Prosight Management, an estimated $7.24M sold.
Based on aggregated 13F filings for Q4 2023.